On the 9th January 2024, NICE (National Institute for Health and Care Excellence) released new guidance to recommend the use of nivolumab-relatlimab within the NHS for people 12 years and over who have untreated, advanced (unresectable or metastatic) melanoma.
After promising trial data, nivolumab-relatlimab received its UK marketing authorisation for use in people who have not previously received treatment for their advanced melanoma. After carrying out an appraisal of all available data, NICE recommend this treatment for people who are not suitable, or choose not to, receive the usual standard treatment with nivolumab and ipilimumab.
Currently a standard treatment for patients with advanced (unresectable or metastatic) melanoma is a combination of two immunotherapy treatments, nivolumab and ipilimumab. If they are not able to receive this treatment combination, for example if doctors are worried they won’t cope too well with the side effects, they will be given immunotherapy treatment with either nivolumab or pembrolizumab alone. Approving the use of nivolumab-relatlimab within the NHS gives these patients another treatment option that could be more effective at treating their melanoma.
For more information and to read the final draft guidance on the use of nivolumab-relatlimab within the NHS see here.